**Yes**, "Hantavirus pulmonary infection" is listed in Pfizer's 5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports (Appendix 1) as one of the Adverse Events of Special Interest (AESIs) for monitoring after rollout.
This was a pre-defined surveillance list of conditions to track closely in post-marketing dataβnot confirmed side effects or events observed in the vaccine trials. The full document was released via FOIA.